XOMA’s (XOMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of XOMA (NASDAQ:XOMA) in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $104.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for XOMA’s Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.

Separately, StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Price Performance

NASDAQ:XOMA opened at $20.88 on Wednesday. XOMA has a 52 week low of $19.92 and a 52 week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The firm’s 50-day simple moving average is $24.37 and its 200 day simple moving average is $27.14. The firm has a market cap of $250.12 million, a price-to-earnings ratio of -6.00 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The business had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, sell-side analysts predict that XOMA will post -1.41 earnings per share for the current year.

Insider Transactions at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of XOMA. BNP Paribas Financial Markets lifted its holdings in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares during the last quarter. New York State Common Retirement Fund lifted its stake in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 800 shares during the last quarter. Wells Fargo & Company MN lifted its stake in XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 1,183 shares during the last quarter. Bank of America Corp DE boosted its position in XOMA by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,009 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of XOMA during the fourth quarter worth $206,000. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.